You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

GASTROCROM Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Gastrocrom, and what generic alternatives are available?

Gastrocrom is a drug marketed by Ucb Inc and Mylan Speciality Lp and is included in two NDAs.

The generic ingredient in GASTROCROM is cromolyn sodium. There are ten drug master file entries for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the cromolyn sodium profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Gastrocrom

A generic version of GASTROCROM was approved as cromolyn sodium by SANDOZ on June 16th, 1999.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for GASTROCROM?
  • What are the global sales for GASTROCROM?
  • What is Average Wholesale Price for GASTROCROM?
Summary for GASTROCROM
Drug patent expirations by year for GASTROCROM
Drug Prices for GASTROCROM

See drug prices for GASTROCROM

Recent Clinical Trials for GASTROCROM

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Early Phase 1
Northwestern UniversityEarly Phase 1
National Heart, Lung, and Blood Institute (NHLBI)Phase 1

See all GASTROCROM clinical trials

Pharmacology for GASTROCROM
Drug ClassMast Cell Stabilizer
Physiological EffectDecreased Histamine Release

US Patents and Regulatory Information for GASTROCROM

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ucb Inc GASTROCROM cromolyn sodium CAPSULE;ORAL 019188-001 Dec 22, 1989 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Mylan Speciality Lp GASTROCROM cromolyn sodium CONCENTRATE;ORAL 020479-001 Feb 29, 1996 AA RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for GASTROCROM

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Ucb Inc GASTROCROM cromolyn sodium CAPSULE;ORAL 019188-001 Dec 22, 1989 ⤷  Sign Up ⤷  Sign Up
Mylan Speciality Lp GASTROCROM cromolyn sodium CONCENTRATE;ORAL 020479-001 Feb 29, 1996 ⤷  Sign Up ⤷  Sign Up
Mylan Speciality Lp GASTROCROM cromolyn sodium CONCENTRATE;ORAL 020479-001 Feb 29, 1996 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for GASTROCROM

See the table below for patents covering GASTROCROM around the world.

Country Patent Number Title Estimated Expiration
Singapore 62587 ⤷  Sign Up
Ireland 812586 ⤷  Sign Up
South Africa 8107572 ⤷  Sign Up
European Patent Office 0051207 A PHARMACEUTICAL MIXTURE CONTAINING SODIUM CROMOGLYCATE AND A METHOD OF MAKING THE MIXTURE ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.